Ontology highlight
ABSTRACT: Background
Metronomic chemotherapy has shown promising activity against solid tumors and is believed to act in an antiangiogenic manner. The current study describes and quantifies the therapeutic efficacy, and mode of activity, of metronomic gemcitabine and a dedicated antiangiogenic agent (DC101) in patient-derived xenografts of pancreatic cancer.Methods
Two primary human pancreatic cancer xenograft lines were dosed metronomically with gemcitabine or DC101 weekly. Changes in tumor growth, vascular function, and metabolism over time were measured with magnetic resonance imaging, positron emission tomography, and immunofluorescence microscopy to determine the anti-tumor effects of the respective treatments.Results
Tumors treated with metronomic gemcitabine were 10-fo
SUBMITTER: Yapp DT
PROVIDER: S-EPMC4819514 | biostudies-literature | 2016 Apr
REPOSITORIES: biostudies-literature